LOS ANGELES, Feb. 11, 2019 /PRNewswire/ -- CytRx
Corporation (NASDAQ: CYTR), a biopharmaceutical research and
development company specializing in oncology, today highlighted
comments from an OncLive® article dated February 1, 2019 that an estimated majority of
oncology patients do not have targetable genetic mutations that
would make them eligible for targeted treatment. Therefore, this
majority of patients are candidates for standard therapies, which
typically include chemotherapy.
Dr. Keith T. Flaherty, ECOG-ACRIN
study chair and a medical oncologist at Massachusetts General
Hospital Cancer Center, noted in the OncLive® article that it
appears roughly 65% of patients do not have potentially targetable
mutations. While progress has been made in some areas for
patients with genetic mutations, and studies like NCI-MATCH (a
precision medicine trial of numerous agents across tumor types)
continue to assess which patients may benefit from therapies
targeting certain genes, for the majority of cancer patients, there
is no targetable genetic mutations.
Centurion BioPharma, a private wholly owned subsidiary of CytRx,
is focused on advancing the Company's proprietary, albumin binding
ultra-high potency LADR™ (Linker-Activated Drug Release) oncology
drug candidates and accompanying companion diagnostic (ACDx) to
improve clinical outcomes for patients with solid tumors.
"Because the majority of cancer patients do not have a
targetable genetic mutation, CytRx believes many of those patients
may be candidates for chemotherapy. Conventional chemotherapy
agents have been a mainstay in standard oncology practice for
decades and remains the relevant approach for the majority of
physicians and patients," Eric
Curtis, President and CEO of Centurion Corporation. "We
believe that our LADR assets and accompanying ACDx will greatly
improve the safety and efficacy of cytotoxic therapy, leading to
better clinical outcomes across a wide variety of solid tumor
types. The ability of LADR to maximize tumor cell kill
potential, while minimizing systemic toxicity, means these assets
can fulfill a significant clinical unmet need. Additionally,
our companion diagnostic shows promise to increase the value of the
LADR pipeline by incorporating a personalized medicine
approach."
About CytRx Corporation
CytRx Corporation (NASDAQ:
CYTR) is a biopharmaceutical company with expertise in discovering
and developing new therapeutics to treat patients with cancer.
CytRx's most advanced drug conjugate, aldoxorubicin, is an improved
version of the widely used anti-cancer drug doxorubicin and has
been out-licensed to NantCell, Inc. In addition, CytRx's
other drug candidate, arimoclomol has been out-licensed to
Orphazyme A/S (Nasdaq Copenhagen exchange). Orphazyme is testing
arimoclomol in four indications including amyotrophic lateral
sclerosis (ALS), Niemann-Pick disease Type C (NPC), Gaucher disease
and sporadic Inclusion Body Myositis (sIBM). CytRx
Corporation's website is www.cytrx.com.
About Centurion Corporation
CytRx's wholly owned
subsidiary, Centurion BioPharma Corporation, is focused on the
development of personalized medicine that is designed to transform
solid tumor treatment. This transformational strategy combines a
portfolio of novel, anti-cancer drug candidates that employ LADR™
(Linker Activated Drug Release) technology, a discovery engine
designed to leverage Centurion's expertise in albumin biology and
linker technology for the development of a new class of
breakthrough anti-cancer therapies with a unique albumin companion
diagnostic (ACDx) that can help identify patients who are most
likely to benefit from treatment with the LADR™-derived therapies.
A critical element of the LADR™ platform is its ability to bind
anti-cancer molecules to circulating albumin, the most ubiquitous
protein in human blood plasma, and then to release the highly
potent cytotoxic payload at the tumor site. This technology allows
for the delivery of higher doses of drug directly to the tumor,
while avoiding much of the off-target toxicity observed with the
patent molecules. Centurion BioPharma Corporation's website is
www.centurionbiopharma.com.
Forward-Looking Statements
This press release contains
forward-looking statements. Such statements involve risks and
uncertainties that could cause actual events or results to differ
materially from the events or results described in the
forward-looking statements, including risks and uncertainties
relating to the ability of targeted therapies to treat cancer
patients in the future; the ability of Centurion BioPharma to enter
into strategic transactions or partnerships involving its
proprietary LADR™ drug candidates and to enter clinical trials or
obtain regulatory approvals for any such products; the efficacy and
safety of such products; the ability of Centurion to develop new
ultra-high potency drug candidates based on its LADR™ technology
platform; or attract potential licensees; and other risks and
uncertainties described in the most recent annual and quarterly
reports filed by CytRx with the Securities and Exchange Commission
and current reports filed since the date of CytRx's most recent
annual report. All forward-looking statements are based upon
information available to CytRx on the date the statements are first
published. CytRx undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:
Argot Partners
Michelle Carroll
(212) 600-1902
michelle@argotpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cytrx-corporation-highlights-majority-of-cancer-patients-do-not-have-targetable-genetic-mutations-and-are-therefore-candidates-for-chemotherapy-300792716.html
SOURCE CytRx Corporation
